EN
ページタイトル画像

Gastroenterology

Overview

Our department is responsible for the research in the entire filed of gastroenterology (liver diseases, biliary diseases, pancreatic diseases, and gastrointestinal diseases). We have the vision to challenge the unmet medical needs in current medical practice. Many clinical challenges remain in both malignant and intractable disease in the filed of gastroenterology. We promote a lot of projects that can be further advanced from both clinical and basic research standpoints. Especially lately, we have been focusing on conducting clinical trials for the development novel treatments, and building a translational research system that allows for the analysis specimens various approaches. In the well-organized research environments, we are challenging to elucidate malignant and intractable disease in the filed of gastroenteroloy from both genetically and immunologically.

Professor:
Naoya Kato M.D., Ph.D.

TEL:+81-43-226-2083
FAX:+81-43-222-2088
e-mail:shokaki●office.chiba-u.jp
URL: https://www.m.chiba-u.ac.jp/dept/gastroenterology/

※　Please change "●" mark to at-mark if you send emails.

17.jpg

Research & Education

Liver diseases
・Comprehensive observational study of chronic liver disease (including primary liver cancer); C-Cube study
■ Primary liver cancer
・Development novel treatments (ex. Immunotherapy combined with carbon-ion radiotherapy [Departure trial], see figure on the right).
・Understanding tumor microenvironment of primary liver cancer and underlying liver disease
■ Acute and chronic hepatitis
■ Decompensated cirrhosis and portal hypertension

Biliary and pancreatic diseases
■ Bile duct and pancreatic cancer
・Analysis of genomic profiling and microbiota in pancreatobiliary cancer using next-generation sequencing
■ Primary sclerosing cholangitis

Gastrointestinal diseases
■ Endoscopic treatment of early-stage cancer
・The development of non-invasive endoscopic treatment and novel diagnosis along with genome analysis.
■ Inflammatory bowel disease
・Large scale observation study of inflammatory bowel disease; Far East 1000

17図.jpg

Immunotherapy combined with carbon-ion radiotherapy for advanced hepatocellular carcinoma patients with macrovascular invasion

Recent Publications

  1. Kobayashi K, Ogasawara S, Takahashi A, et al. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2021 Dec 6;11(1):48-60.
  2. Koroki K, Ogasawara S, Ooka Y, et al. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer. 2020 Sep;9(5):596-612.
  3. Okimoto K, Maruoka D, Matsumura T, et al. Appropriate selection of endoscopic resection for superficial nonampullary duodenal adenomas in association with recurrence. Gastrointest Endosc. 2022 Jan 20:S0016-5107(22)00042-6.
  4. Kusakabe et al. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Sci Rep. 2021 Nov 1;11(1):21396.
  5. Asano et al. Analysis of circulating cell-free DNA after endoscopic ultrasound-guided fine needle aspiration in pancreatic ductal adenocarcinoma. Pancreatology. 2021 Apr 15;S1424-3903(21)00140-X.
  6. Akizue et al. Comprehensive mutational analysis of background mucosa in patients with Lugol-voiding lesions. Cancer Med. 2021 Jun;10(11):3545-3555.